文献速递妇科

曲妥珠单抗联合卡铂/紫杉醇治疗晚期及复发性子宫乳头状浆液性癌的成本效果分析

Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
PubMed 文献 · Gynecol Oncol · 2020-10-22

本研究采用Markov模型模拟4000例Her2/neu阳性晚期或复发性子宫乳头状浆液性癌(UPSC)患者,比较卡铂/紫杉醇联合曲妥珠单抗与单纯化疗的成本效果。结果显示联合曲妥珠单抗可减少死亡和进展,增量成本效果比(ICER)为每QALY 69,903美元,低于10万美元/QALY的支付意愿阈值,结论为具有成本效果。

要点

  • 联合曲妥珠单抗较单纯化疗减少637例死亡和627例进展。
  • ICER为每QALY 69,903美元,低于10万美元/QALY阈值。
  • 敏感性分析显示治疗6个月成本超过38,505美元时不再具有成本效果。

核心结论

  • 在Her2/neu阳性晚期或复发性UPSC患者中,卡铂/紫杉醇联合曲妥珠单抗较单纯化疗具有成本效果。

研究设计与样本

  • 研究使用TreeAge Pro 2019软件构建Markov模型,模拟4000例Her2/neu阳性晚期或复发性UPSC患者,随访4年,采用社会视角,模型输入来自文献。

主要发现

  • 联合曲妥珠单抗组较单纯化疗组减少637例死亡和627例进展。
  • 联合曲妥珠单抗组增加成本144,335,895美元,增加2065个QALYs。
  • ICER为每QALY 69,903美元,低于100,000美元/QALY的支付意愿阈值。

关键数值与推荐

  • 成本效果判定阈值:ICER低于100,000美元/QALY。
  • 敏感性分析:治疗6个月成本超过38,505美元时不再具有成本效果(基线输入为27,562美元)。

临床怎么用

  • 对于Her2/neu阳性晚期或复发性UPSC患者,可考虑在卡铂/紫杉醇基础上加用曲妥珠单抗,但需结合当地支付意愿和药物成本评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Uterine papillary serous carcinoma (UPSC) is a variant of endometrial cancer that is aggressive and associated with poor outcomes. We sought to evaluate the cost effectiveness of carboplatin/paclitaxel alone versus carboplatin/paclitaxel with trastuzumab among patients with Her2/neu-positive advanced or recurrent UPSC. METHODS: We designed a Markov model in TreeAge Pro 2019 software to simulate management of a theoretical cohort of 4000 patients with Her2/neu-positive advanced or recurrent uterine papillary serous carcinoma (UPSC) followed for four years. In the carboplatin/paclitaxel with trastuzumab strategy, we included the cost of testing for Her2/neu status. We obtained all model inputs from the literature and a societal perspective was assumed. Outcomes included progression-free survival, progression, UPSC-specific mortality, cost, and quality-adjusted life years (QALYs). The intervention was considered cost effective if the incremental cost-effectiveness ratio (ICER) was below the willingness-to-pay threshold of $100,000 per QALY. Sensitivity analyses were used to determine the robustness of the results. RESULTS: In our theoretical cohort of 4000 women, treatment with the addition of trastuzumab resulted in 637 fewer deaths and 627 fewer cases of progression compared with treatment with carboplatin/paclitaxel alone. Treatment with trastuzumab was associated with an additional cost of $144,335,895, but was associated with an increase of 2065 QALYs. The ICER was $69,903 per QALY, which was below our willingness-to-pay threshold. Sensitivity analysis demonstrated that this treatment strategy was cost-effective until the cost of 6 months of treatment surpassed $38,505 (baseline input: $27,562). CONCLUSION: We found that the addition of trastuzumab to carboplatin/paclitaxel was a cost-effective treatment strategy for patients with advanced/recurrent Her2/neu-positive UPSC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Batman S, Bohn J, Weisenberger MW, et al. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis. Gynecol Oncol. 2020. PMID: 33393480. doi:10.1016/j.ygyno.2020.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。